Alexion - About the company
Alexion is an acquired company based in Zurich (Switzerland), founded in 1992 by Steve Squinto, David Keiser, Joseph Madri and Leonard Bell. It operates as a Developer of therapies for patients with devastating and rare diseases. Alexion has raised $133M in funding from investors like Allen & Company, Connecticut Innovations and Invesco. The company has 464 active competitors, including 133 funded and 154 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.
Company Details
Developer of therapies for patients with devastating and rare diseases. The company has developed therapeutics for hematology, nephrology, neurology, metabolic, and cardiology disorders. Alexion developed Soliris which is a terminal complement inhibitor for the treatment of myasthenia gravis and Ultomiris for the hemolytic uremic syndrome.
- Website
- alexion.com
- Social
- Email ID
- *****@alexion.com
- Registered Address
- Boston, Massachusetts
Key Metrics
Founded Year
1992
Location
Zurich, Switzerland
Stage
Acquired
Total Funding
$133M in 11 rounds
Latest Funding Round
Investors
Ranked
3rd among 464 active competitors
Employee Count
5,119 as on Apr 30, 2026
Exit Details
Acquired by AstraZeneca (Dec 12, 2020)
Legal entities associated with Alexion
Alexion is associated with 9 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Alexion Pharmaceuticals, Inc. CIN: 133648318 , United States, Active | Dec 26, 999 | $1B+ (As on Dec 31, 2020) | 2111 (As on Dec 31, 2020) | - |
ACHILLION PHARMACEUTICALS INC CIN: 1070336 , United States, Active | Aug 04, 1998 | - | - | - |
ALEXION CORP CIN: 811945952 , United States, Active | Dec 26, 999 | - | 1 (As on Dec 31, 2022) | - |
Alexion Pharmaceuticals, Inc. CIN: 10222349 , United States, Active | Jan 02, 2023 | - | - | - |
Portola Pharmaceuticals Inc CIN: 1269021 , United States, Active | Sep 01, 2003 | $100M - $500M (As on Dec 31, 2019) | - | - |
Alexion Pharma GmbH CIN: 883913 , Switzerland, Active | May 21, 2024 | - | - | - |
ALEXION BUSINESS SERVICES PRIVATE LIMITED CIN: U74120MH2011PTC218281 , India, Active | Jun 03, 2011 | 0 - ₹10 Cr (As on Mar 31, 2024) | 2 (As on Jun 30, 2023) | |
Alexion Pharmaceuticals Inc CIN: 899866 , United States, Active | Nov 30, 2020 | $1B+ (As on Dec 31, 2017) | - | - |
Alexion Pharma Czech s.r.o. CIN: 03516971 , Czech Republic, Active | Oct 24, 2014 | - | - |
Alexion's acquisition details
Alexion got acquired by AstraZeneca on Dec 12, 2020 at an acquisition amount of $*****.
Click here to take a look at Alexion's acquisition in detail
Sign up to download Alexion's company profile
Alexion's funding and investors
Alexion has raised a total funding of $133M over 11 rounds. Its first funding round was on Jun 29, 1993. Alexion has 11 institutional investors.
Here is the list of recent funding rounds of Alexion:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 15, 2018 | 7880242 | Conventional Debt | 7223606 | 1771523 | 8450036 | 9687270 |
2016 | 4421 | Post IPO | 5382 | 8392 | 7387 | |
Jun 2015 | 3076153 | Conventional Debt | 7028015 | 1834526 | 9928140 | 7715435 |
Access funding benchmarks and valuations. Sign up today!View details of Alexion's funding rounds and investors
Alexion's founders and board of directors
Founder? Claim ProfileThe founders of Alexion are Steve Squinto, David Keiser, Joseph Madri and Leonard Bell. Ludwig Hantson and Lisa Ballard are the CEOs of Alexion.
Here are the details of Alexion's key team members:
- Steve Squinto: Former Co-Founder of Alexion.
- David Keiser: Ex- President and Chief Operating Officer of Alexion.
- Joseph Madri: Director of Alexion.
- Leonard Bell: Co-Founder of Alexion.
- Michael Kishbauch: CEO of Alexion.
View details of Alexion's Founder profiles and Board Members
Alexion's employee count trend
Alexion has 5,119 employees as of Apr 26. Here is Alexion's employee count trend over the years:
Uncover Alexion's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Alexion's Competitors and alternates
Top competitors of Alexion include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Alexion, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BridgeBio 2015, Palo Alto (United States), Public | Developer of therapeutics for the treatment of genetic diseases | $434M | 81/100 | |
2nd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
3rd | Alexion 1992, Zurich (Switzerland), Acquired | Developer of therapies for patients with devastating and rare diseases | $133M | 79/100 | |
4th | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 77/100 | |
5th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 74/100 | ||
6th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
7th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
8th | Bluebird Bio 1992, Cambridge (United States), Acquired | Developer of gene therapies for severe genetic and rare diseases | $136M | 71/100 | |
9th | Agios Pharmaceuticals 2008, Cambridge (United States), Public | Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism | $120M | 70/100 | |
10th | Rhythm Pharmaceuticals 2010, Boston (United States), Public | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | $84M | 70/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Alexion's competitors? Click here to see the top ones
Alexion's Investments and acquisitions
Alexion has made 2 investments in companies including Moderna and Moderna. Alexion has also acquired 6 companies including LogicBio and Portola Pharma.Here is the list of investments & acquisitions:Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Oct 03, 2022 | Acquisition | 2013 | Lexington (United States) | |
May 05, 2020 | Acquisition | 2003 | San Francisco (United States) | |
Apr 11, 2018 | Acquisition | 2012 | Stockholm (Sweden) |
Want to know more about where corporates are investing? Sign up today!See all acquisitions by Alexion
News related to Alexion
Filter this listMedia has covered Alexion for a total of 8 events in the last 1 year, 4 of them have been about company updates and 2 about partnerships.
•
•
Alexion adopts 100% renewable energy in Ireland with biomethane agreementBioenergy Insight•Nov 24, 2025•Carbon AMS, Alexion, AstraZeneca
•
JCR Pharma & Alexion Achieve Milestone in Neurodegenerative Disease ProgramBusiness Wire•Sep 19, 2025•JCR Pharmaceuticals, Alexion
•
•
AstraZeneca drug from Alexion deal succeeds in autoimmune disease trial.BioPharmaDive•Jul 24, 2025•AstraZeneca, Alexion
•
JCR Pharma and Alexion partner on JUST-AAV gene therapy platform
Pharmaceutical Technology•Jul 09, 2025•JCR Pharmaceuticals, Alexion, AstraZeneca
•
JCR Pharmaceuticals Enters License Agreement with Alexion for JUST-AAV CapsidsBusiness Wire•Jul 08, 2025•JCR Pharmaceuticals, Alexion
•
Pangaea Data, Alexion Collaboration, Dell to Develop Supercomputer, MoreBio-IT World•Jun 24, 2025•Pangaeadata Ai, Alexion
•
Coave Therapeutics Expands US Presence with Key AppointmentGlobeNewswire•Apr 23, 2025•Coave Therapeutics, Alexion
•
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private EquityMedCity News•Feb 22, 2025•Bluebird Bio, The Carlyle Group, SK Capital, Pfizer and 8 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Alexion
Explore our recently published companies
- Autocal - Thane based, 2002 founded, Funding Raised company
- Indo Amines - Thane based, 1994 founded, Public company
- Taro International - Haifa based, 1992 founded, Unfunded company
- SmartCart AI - San Francisco based, Unfunded company
- 365 Retail Markets - London based, 2008 founded, Unfunded company
- Bishop Paiute Development Corporation - Bishop based, 2009 founded, Funding Raised company
